Published in Int J Immunopharmacol on January 01, 1981
Sexually transmitted diseases, T cell subsets, and sexual practices in homosexual men attending an STD clinic. Genitourin Med (1985) 1.40
T-lymphocyte subpopulations in relation to immunosuppression in measles and varicella. Infect Immun (1983) 1.37
Nonrandom development of immunologic abnormalities after infection with human immunodeficiency virus: implications for immunologic classification of the disease. Proc Natl Acad Sci U S A (1987) 1.24
Relationship between T cell subsets and suppressor cell activity in chronic hepatitis B virus (HBV) infection. Clin Exp Immunol (1983) 1.04
The acquired immune deficiency syndrome (AIDS)--a multidisciplinary enigma. West J Med (1984) 0.96
Studies on immunoregulatory mechanisms in acute and chronic hepatitis B. Clin Exp Immunol (1983) 0.91
Deficient natural killer cell activity in alcoholic cirrhosis. Clin Exp Immunol (1984) 0.89
Acquired immune dysfunction in homosexual men. West J Med (1982) 0.75
Increase in primary liver cancer in the UK, 1979-94. Lancet (1997) 6.15
Vaccine-induced escape mutant of hepatitis B virus. Lancet (1990) 5.31
Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet (1989) 5.16
Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A (1996) 4.02
Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut (2002) 4.01
Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med (1995) 3.54
Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut (2001) 3.45
Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology (1998) 3.31
Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol (1978) 3.06
Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet (2000) 2.58
The induction of tolerance to a soluble protein antigen by oral administration. Immunology (1974) 2.50
Is primary biliary cirrhosis an immune complex disease? Lancet (1977) 2.15
Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology (1989) 2.15
Role of the liver in controlling the immunogenicity of commensal bacteria in the gut. Lancet (1973) 2.15
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat (2011) 2.00
Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Gastroenterology (1994) 2.00
Immune complexes in acute and chronic liver disease. Clin Exp Immunol (1978) 1.93
Evidence for a cerebral effect of the hepatitis C virus. Lancet (2001) 1.90
Incidence and clinical significance of e antigen and antibody in acute and chronic liver disease. Lancet (1975) 1.90
Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun (2003) 1.88
Antenatal screening for hepatitis B is medically and economically effective in the prevention of vertical transmission: three years experience in a London hospital. Q J Med (1989) 1.88
The detection of HBV-DNA in serum by molecular hybridisation: a more sensitive method for the detection of complete HBV particles. J Med Virol (1982) 1.81
Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat Genet (1997) 1.71
Short incubation non-A, non-B hepatitis transmitted by factor VIII concentrates in patients with congenital coagulation disorders. Gut (1981) 1.67
Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA. Proc Natl Acad Sci U S A (1991) 1.64
Effects of cyclosporin A on suppressor and inducer T lymphocytes in primary biliary cirrhosis. Lancet (1980) 1.61
Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess (2006) 1.50
Is mitochondrial antibody diagnostic of primary biliary cirrhosis? Gut (1981) 1.50
Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet (1984) 1.49
Loss of the common "A" determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest (1992) 1.48
Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology (1997) 1.47
Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology (1985) 1.45
Detection of serum HBV-DNA by molecular hybridisation. Correlation with HBeAg/anti-HBe status, racial origin, liver histology and hepatocellular carcinoma. J Hepatol (1985) 1.43
Peripheral blood lymphocyte populations in chronic liver disease. Clin Exp Immunol (1976) 1.43
Pseudomembranous colitis following clarithromycin therapy. Eur J Gastroenterol Hepatol (1995) 1.40
Significance of delta agent infection in chronic hepatitis B virus infection: a study in British carriers. Gut (1983) 1.40
Recent advances in the molecular biology of hepatitis B virus: mutant virus and the host response. Gut (1993) 1.39
Adenine arabinoside therapy in HBsAg-positive chronic liver disease: a controlled study. Gastroenterology (1981) 1.38
SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther (2000) 1.37
Primary biliary cirrhosis is a dry gland syndrome with features of chronic graft-versus-host disease. Lancet (1980) 1.36
Hepatitis B virus and HLA antigen display in the liver during chronic hepatitis B virus infection. Hepatology (1982) 1.36
Double-stranded DNA-binding capacity of serum in acute and chronic liver disease. Clin Exp Immunol (1976) 1.35
Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology (1998) 1.33
Cytotoxic T-cell responses to the nucleocapsid proteins of HBV in chronic hepatitis. Evidence that antibody modulation may cause protracted infection. J Hepatol (1987) 1.33
Protection against hepatitis B virus infection by immunization with hepatitis B core antigen. Gastroenterology (1985) 1.32
HLA class I antigens on the hepatocyte membrane during recovery from acute hepatitis B virus infection and during interferon therapy in chronic hepatitis B virus infection. Hepatology (1986) 1.31
Genetic variation in hepatitis B virus. Gastroenterology (1992) 1.29
Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis. Hepatology (1991) 1.29
HLA-B8, immunoglobulins, and antibody responses in alcohol-related liver disease. J Clin Pathol (1980) 1.28
Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology (1996) 1.27
A rapid one-step radiometric assay for hepatitis B surface antigen utilizing monoclonal antibodies. J Immunol Methods (1982) 1.26
Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut (2005) 1.26
An analysis of the composition of the inflammatory infiltrate in autoimmune and hepatitis B virus-induced chronic liver disease. Hepatology (1983) 1.25
Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. BMJ (1997) 1.24
The immune response in hepatic cirrhosis: animal and human studies. Proc R Soc Med (1977) 1.23
Seroprevalence of hepatitis C virus nucleocapsid antibodies in patients with cryptogenic chronic liver disease. Hepatology (1992) 1.22
Sequence variation in the large envelope glycoprotein (E2/NS1) of hepatitis C virus during chronic infection. J Infect Dis (1993) 1.22
Reduction of immune complexes and immunoglobulins induced by D-penicillamine in primary biliary cirrhosis. N Engl J Med (1979) 1.22
Inducer and suppressor T-cells in hepatitis B virus-induced liver disease. Hepatology (1982) 1.20
The mechanism of replication of hepatitis B virus: evidence of asymmetric replication of the two DNA strands. J Med Virol (1984) 1.18
Staurosporine-induced apoptosis in cardiomyocytes: A potential role of caspase-3. J Mol Cell Cardiol (1998) 1.17
Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research. Eur J Gastroenterol Hepatol (2000) 1.16
HBsAg-positive chronic liver disease: inhibition of DNA polymerase activity by vidarabine. Br Med J (1978) 1.15
High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin. Br J Haematol (1985) 1.15
Antiviral therapy in hepatitis B infection. Br Med Bull (1985) 1.15
Oral infections with Candida albicans. Scott Med J (1973) 1.15
Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of origin. J Viral Hepat (2009) 1.14
A unique insertion in the S gene of surface antigen--negative hepatitis B virus Chinese carriers. Hepatology (1995) 1.14
Lymphocyte populations in liver biopsy specimens from patients with chronic liver disease. Gut (1977) 1.13
Effect of variation in the common "a" determinant on the antigenicity of hepatitis B surface antigen. J Med Virol (2000) 1.13
Acute type A, B, and non-A, non-B hepatitis in a hospital population in London: clinical and epidemiological features. Gut (1983) 1.13
Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat (2003) 1.13
Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. Gastroenterology (1999) 1.12
Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life. Hepatology (1986) 1.12
In-vitro synthesis of anti-acetylcholine-receptor antibody by thymic lymphocytes in myasthenia gravis. Lancet (1978) 1.12
Haemorrhagic pancreatitis--a cause of death in severe potassium permanganate poisoning. Postgrad Med J (1990) 1.11
Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers. Lancet (1987) 1.09
Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection. Genes Immun (2002) 1.09
Cerebral microglial activation in patients with hepatitis C: in vivo evidence of neuroinflammation. J Viral Hepat (2011) 1.09
Ablative therapy for liver tumours. Gut (2002) 1.08
Immune response to phi X 174 in man. 5. Primary and secondary antibody production in primary biliary cirrhosis. Gut (1976) 1.08
A homeostatic mechanism for the removal of antigen from the portal circulation. Immunology (1974) 1.05
Fast and slow twitch muscles in man. J Neurol Sci (1969) 1.05
Food antibodies in oral disease: a study of serum antibodies to food proteins in aphthous ulceration and other oral diseases. J Clin Pathol (1973) 1.04
Diminished responsiveness of homosexual men to antiviral therapy for HBsAg-positive chronic liver disease. J Hepatol (1985) 1.04
Expression of beta-2-microglobulin on hepatocytes after liver transplantation. Lancet (1985) 1.04
Identification of a dominant immunogenic epitope of the nucleocapsid (HBc) of the hepatitis B virus. J Med Virol (1986) 1.04
Cloning and characterisation of a delta virus cDNA sequence derived from a human source. J Med Virol (1987) 1.04
Antibodies to Escherichia coli in chronic liver diseases. Gut (1975) 1.03
Primary liver cell cancer in Britain--a viral aetiology? Br Med J (1979) 1.02
Different relative activities of human cell-derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency. J Interferon Cytokine Res (1996) 1.02
Hepatitis B virus DNA in saliva, urine, and seminal fluid of carriers of hepatitis B e antigen. Br Med J (Clin Res Ed) (1985) 1.02
A randomized study of the effects of adenine arabinoside 5'-monophosphate (short or long courses) and lymphoblastoid interferon on hepatitis B virus replication. Hepatology (1985) 1.02
The clinical significance of molecular variation within the hepatitis B virus genome. Hepatology (1992) 1.02
Monoclonal antibodies in a solid-phase radiometric assay for HBsAg. Med Lab Sci (1981) 1.01
Cloning and sequencing of RNA of hepatitis delta virus isolated from human serum. J Gen Virol (1990) 1.01